
Rapport Therapeutics, Inc. (NASDAQ:RAPP - Free Report) - Stock analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for shares of Rapport Therapeutics in a research note issued on Wednesday, August 6th. HC Wainwright analyst D. Tsao forecasts that the company will post earnings of ($0.71) per share for the quarter. HC Wainwright has a "Buy" rating and a $31.00 price objective on the stock. The consensus estimate for Rapport Therapeutics' current full-year earnings is ($3.65) per share. HC Wainwright also issued estimates for Rapport Therapeutics' Q3 2025 earnings at ($0.70) EPS, Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at ($2.79) EPS, FY2026 earnings at ($3.14) EPS, FY2027 earnings at ($3.64) EPS, FY2028 earnings at ($4.44) EPS and FY2029 earnings at ($4.07) EPS.
Separately, JMP Securities reissued a "market outperform" rating and issued a $28.00 price objective on shares of Rapport Therapeutics in a research report on Tuesday, July 8th.
Read Our Latest Research Report on Rapport Therapeutics
Rapport Therapeutics Stock Performance
Shares of RAPP stock traded down $0.86 during mid-day trading on Friday, hitting $14.55. The company's stock had a trading volume of 104,519 shares, compared to its average volume of 165,562. The company's fifty day simple moving average is $13.21 and its 200-day simple moving average is $11.95. Rapport Therapeutics has a 52 week low of $6.43 and a 52 week high of $29.74. The company has a market cap of $531.08 million, a PE ratio of -5.82 and a beta of 0.62.
Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.75) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.12.
Institutional Trading of Rapport Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Intech Investment Management LLC bought a new stake in Rapport Therapeutics in the 2nd quarter valued at about $130,000. Creative Planning bought a new stake in Rapport Therapeutics in the 2nd quarter valued at about $121,000. Geode Capital Management LLC increased its position in Rapport Therapeutics by 5.5% in the 2nd quarter. Geode Capital Management LLC now owns 333,159 shares of the company's stock valued at $3,789,000 after buying an additional 17,496 shares in the last quarter. TD Asset Management Inc increased its position in Rapport Therapeutics by 20.9% in the 2nd quarter. TD Asset Management Inc now owns 196,870 shares of the company's stock valued at $2,238,000 after buying an additional 34,052 shares in the last quarter. Finally, Rhumbline Advisers increased its position in Rapport Therapeutics by 40.1% in the 1st quarter. Rhumbline Advisers now owns 14,358 shares of the company's stock valued at $144,000 after buying an additional 4,109 shares in the last quarter.
Insider Buying and Selling
In related news, insider David Bredt sold 8,500 shares of the business's stock in a transaction dated Tuesday, July 15th. The stock was sold at an average price of $14.00, for a total value of $119,000.00. Following the completion of the sale, the insider directly owned 435,142 shares of the company's stock, valued at $6,091,988. The trade was a 1.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Rapport Therapeutics Company Profile
(
Get Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
See Also
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.